Skip to main content
. 2022 Apr 9;4(1):vdac047. doi: 10.1093/noajnl/vdac047

Figure 1.

Figure 1.

RABL6A promotes MPNST progression in both Nf1 + Cdkn2a and Nf1 + p53 targeted primary MPNST mouse models. Adenoviral CRISPR-Cas9 targeting of Nf1 + Cdkn2a or Nf1 + p53 was performed in the sciatic nerve of wildtype (WT) or Rabl6 knockout (KO) C57BL/6N mice to generate primary MPNSTs. (A) Schematic of CRISPR-Cas9 targeting constructs with sgRNAs against Nf1 with p16Ink4a and p19Arf (together comprise the Cdkn2a locus), designated NC, or sgRNAs against Nf1 and p53, designated NP. U6 and CMV promoters are indicated. (B) Fold change in tumor volume shows mice lacking Rabl6 display slower tumor growth kinetics in both NC and NP genetic settings. (C) Time (in days) for tumors to triple in size in WT versus Rabl6 KO mice. (D) Survival (time to maximum 2000 mm3 tumor volume) of WT versus Rabl6 KO mice. Error bars, SEM. B: P value determined by a generalized linear model to assess the difference between the curves. C–D: P value, Student’s t-test for KO versus WT comparisons per genotype (*, P < .05; ***, P < .001).